Auryxia
(ferric citrate)ApprovedSmall molecule
Ferric citrate is used to treat high phosphorus levels in the blood in patients with kidney disease, and it also helps treat iron deficiency anemia in people with chronic kidney disease who are on dialysis.[2] Auryxia is currently approved and in use across 4 indications[4].[1]
Auryxia is one of 96 small molecule programs targeting Anemia. It is currently in Approved.
4
Indications
20
Total Trials
3
Active Trials
95
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
172 competitors in Chronic Kidney Disease
#DrugCompanyPhaseTrials
1Auryxia
KKeryx Biopharmaceuticals
Approved
Uloric
TakedaPreclinical
Sovaldi
GileadPreclinical
Glucotrol
PfizerPreclinical
Vemlidy
GileadPreclinical
Lorelco
SanofiPreclinical
Activase
RochePreclinical
Flomax
SanofiPreclinical
Januvia
ZZydus Therapeutics Inc.
Preclinical
Verquvo
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Kidney Disease6 trials
Show 3 more trials
End-Stage Renal Disease3 trials
End Stage Renal Disease (ESRD)3 trials
Peritoneal Dialysis1 trial
6 more indications
Iron-deficiency1 trial
Adult Subject1 trial
Regulatory
FDA Approval Timeline[5]
Sep 5, 2014
AURYXIA
NDA NDA205874
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Auryxia drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for ferric citrate. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- KKeryx Biopharmaceuticals